Emodin on hepatic fibrosis in rats

被引:0
作者
Zhan, YT [1 ]
Li, DG [1 ]
Wei, HS [1 ]
Wang, ZR [1 ]
Huang, X [1 ]
Xu, QF [1 ]
Lu, HM [1 ]
机构
[1] Shanghai Second Med Univ, Xinhu Hosp, Dept Gastroenterol, Shanghai 200092, Peoples R China
关键词
emodin; hepatic fibrosis; liver functions; animal model;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective To investigate effect of emodin on hepatic fibrosis in rats. Methods The rat hepatic fibrosis model was induced by the subcutaneous injection of 40% CCl4 (twice a week for 6 weeks) dissolved in olive oil. The emodin-treated rats were treated with low-dose, mediate-dose and high-dose emodin (20, 40 and 80 mg/kg body weight, once a day for 42 days) dissolved in 0.5% sodium carboxymethylcellulose ( CMC), except receiving CCl4. Control group received only olive oil and 0.5% CMC. Liver functions were determined by standard procedure. Serum hyaluronic acid and laminin were determined by radioimmunoassay. Liver hydroxyprolines were determined. Histopathological changes were examined by optical microscopy. Results Compared with model group, the emodin-treated rats showed (1) liver functions were improved, alanine transaminase (ALT) and alkaline phosphatase (AKP) were obviously reduced, and total protein (TP) and albumin (ALB) were significantly increased; (2) serum hyaluronic acid and laminin were markedly reduced; (3) liver hydroxyproline was significantly decreased; (4) the degrees of fibrosis were reduced. The changes of parameters mentioned above were significant (P<0.05 or P<0.01). Conclusion Emodin has effect on hepatic fibrosis in rats. The hepatoprotective of emodin may be one of mechanisms for liver fibrosis.
引用
收藏
页码:599 / 601
页数:3
相关论文
共 9 条
[1]   Cellular networks in hepatic fibrosis [J].
Friedman, SL .
DIGESTION, 1998, 59 (04) :368-371
[2]  
GOU KB, 1997, CHIN PHARM J, V32, P278
[3]   Serum markers as tools to monitor liver fibrosis [J].
Hayasaka, A ;
Saisho, H .
DIGESTION, 1998, 59 (04) :381-384
[4]  
LIU YZ, 1998, ACTA BIOPHYS SINICA, V14, P241
[5]  
Liu ZH, 1996, ACTA PHARM SINIC, V17, P61
[6]  
Loreal O, 1997, Rev Prat, V47, P482
[7]  
SCHVAREZ R, 1993, J HEPATOL, V4, P277
[8]  
WANG AM, 1998, CHIN J DIG, V18, P213
[9]   Antifibrogenic effect of a deletion variant of hepatocyte growth factor on liver fibrosis in rats [J].
Yasuda, H ;
Imai, E ;
Shiota, A ;
Fujise, N ;
Morinaga, T ;
Higashio, K .
HEPATOLOGY, 1996, 24 (03) :636-642